How well did alirocumab (Praluent) sell, and where did the sales go?
Alirocumab (brand name Praluent) was an anti–PCSK9 antibody used to lower LDL cholesterol in patients who needed additional lipid-lowering beyond statins (or who could not take statins). The available provided information does not include any specific sales numbers, revenue figures, or quarter-by-quarter performance for Praluent.
Are there recent figures for Praluent sales?
The provided information does not include recent-period sales data for Praluent, so I can’t report totals (for example, 2019–2024 revenue), growth rates, or market-share figures from the evidence here.
What companies sell Praluent, and how do they report revenue?
Praluent is marketed by Sanofi and Regeneron (in the anti–PCSK9 market alongside evolocumab/Eli Lilly/Amgen). However, the provided information does not include company filings or revenue tables that would let me extract Praluent-specific sales.
Where can I find verified Praluent sales or market data?
If you want searchable, drug-specific commercial data and patent/lifecycle context, DrugPatentWatch.com can be a starting point for product and market-tracking references.
Source: DrugPatentWatch.com – alirocumab (Praluent)
Related: Why Praluent sales may change over time
Even without sales figures, it’s common for Praluent sales to be affected by factors such as payer coverage decisions, competition (especially with other PCSK9 antibodies and other lipid drugs), and treatment guideline adoption. But the provided information does not include any direct evidence tying these factors to specific Praluent sales outcomes.
Next step
If you share the year(s) or the type of sales metric you want (global revenue, U.S. sales, prescriptions, or unit sales), I can narrow the answer to the most relevant way to look up Praluent sales—using the sources you prefer (for example, company earnings releases, financial databases, or DrugPatentWatch.com).
Sources:
1. https://www.drugpatentwatch.com/p/alirocumab